.png)
Merck KGaA, a premier science and technology company, today revealed up to-date Phase 3 data from the global MANEUVER trial of pimicotinib, an investigational CSF-1R antagonist developed in collaboration with Abbisko Therapeutics for the treatment...
Eli Lilly and Cipla have signed a strategic cooperative agreement to distribute and promote tirzepatide in India. Cipla will create a new brand, Yurpeak, to expand access to the drug in areas beyond cities where Lilly is already present.
Austria's Modern Mayr Medicine, a world leader in gut health and natural preventive medicine, has announced a historic strategic relationship with Biopeak, India's first full-stack precision health and wellness platform
Glenmark Pharmaceuticals Inc., USA, has announced the upcoming launch of its Ropivacaine Hydrochloride Injection USP in three single-dose vial strengths
Alembic Pharmaceuticals Limited has secured final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Triamcinolone Acetonide Injectable Suspension USP
Roche revealed promising results from two pivotal Phase III trials, MEERKAT and SANDCAT, assessing vamikibart, an investigational non-steroidal medication for uveitic macular edema (UME). UME is attributable to inflammation and an accumulation...
In patients with advanced endometrial cancer, five-year data from the Phase 3 KEYNOTE-775/Study 309 trial revealed a durable survival benefit for KEYTRUDA plus LENVIMA compared to chemotherapy, according to Merck, which is known as MSD outside of the
The Competition Commission of India (CCI) on Tuesday approved Torrent Pharmaceuticals Ltd’s proposed acquisition of a stake in JB Chemicals and Pharmaceuticals, contingent upon certain voluntary modifications submitted by both companies
A new therapy developed by AstraZeneca and Daiichi Sankyo has demonstrated significant success in a major clinical trial targeting an aggressive and difficult-to-treat form of breast cancer, potentially paving the way for regulatory approval
The U.S. Food and Drug Administration (FDA) has authorized TEZSPIRE (tezepelumab-ekko) for the add-on maintenance therapy of poorly managed chronic rhinosinusitis with nasal polyps (CRSwNP) in adults and pediatric patients aged 12 years and above
.jpg)
, CDSCO.jpg)